Evidence map›Paper›PMID 29196356›Full record

ReviewClinical medicine (London, England)2017

The rise of the genome and personalised medicine.

Helen K Brittain, Richard Scott, Ellen Thomas

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical medicine (London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 2 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 2 syntheses or guidelines pooled it, 190 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Structured engineering of self-emulsifying drug delivery systems (SEDDS)International journal of pharmaceutics: X · 2025
    Review
  12. Article
  13. Article
  14. Observational
  15. Review
  16. Review
  17. Review
  18. Personalized Medicine in Treating Rare Genetic Disorders: A Review.Journal of pharmacy & bioallied sciences · 2025
    Review
  19. Review
  20. Review

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Helen K BrittainGreat Ormond Street Hospital, London, UK, Queen Mary University of London, UK and Genomics England, London, UK helen.brittain@genomicsengland.co.uk.
Richard ScottGreat Ormond Street Hospital, London, UK and Genomics England, London, UK.
Ellen ThomasGuy's and St Thomas' NHS Foundation Trust, London, UK, Queen Mary University of London, UK and Genomics England, London, UK.
Genomics England · GBGreat Ormond Street Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Virtually all medical specialties are impacted by genetic disease. Enhanced understanding of the role of genetics in human disease, coupled with rapid advancement in sequencing technology, is transforming the speed of diagnosis for patients and providing increasing opportunities to tailor management. As set out in the

Indexed as

Ethics, MedicalGenetic CounselingGenetic Predisposition to DiseaseGenetic TestingGenome, HumanGenomicsHumansNeoplasmsPrecision MedicineState MedicineUnited KingdomWhole Genome SequencingEthicsgenomicspersonalised medicinevariant classification and whole genome sequencing

Identifiers

PMID29196356
PMCPMC6297695
OpenAlexW2773318670

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.